PGN-OB1: liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the OBDS for the treatment of autoimmune conditions
We are developing PGN-OB1 as a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. Several anti-TNF-alpha antibodies have been approved to treat a range of inflammatory conditions. However, all require either intravenous or subcutaneous injection. Adalimumab is approved for a range of inflammatory disorders and is the best-selling drug globally. An oral variant of adalimumab presents a significant opportunity for the many patients who would like to avoid painful injections.
PGN-OB1 is currently in preclinical stage development with a formulation that we have developed and scaled to GMP grade material.
PGN-OB2: liquid formulation of a GLP-1 receptor agonist delivered with the OBDS for the treatment of Type 2 diabetes
We are developing PGN-OB2 as a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. GLP-1RAs are a leading class of therapeutics for type 2 diabetes. We believe oral GLP-1RAs will be preferred by patients to injectables, resulting in a significant market opportunity.
We are currently advancing development of PGN-OB2 with key preclinical studies. As a result of our use of known molecules, we believe that rapid proof of concept with preclinical and phase 1 pharmacokinetic results is possible.
Connect with us